Answers are grounded in this paper and cite their sources.
Type 2 diabetes is one of the major chronic diseases accounting for a substantial proportion of disease burden in Western countries. Its prevalence has been increasing over decades and is estimated to affect 642 million of people worldwide by 2040.1 This is due to the pandemic of overweight in our society, ageing of the population and improved diabetes management and treatment. In the year 1989, the Hoorn Study was initiated to study the prevalence and risk factors of impaired glucose metabolism and type 2 diabetes in a Western European population.2 This initially cross-sectional study has been extended to a prospective cohort over the past decades, to study the complications associated with disturbances in glucose metabolism and diabetes care. In the year 2006, a second, similar cohort was initiated, the New Hoorn Study based on the design of the earlier Hoorn Study.3 The primary objective now was to investigate whether the increasing rates of longevity, physical inactivity and obesity affect the prevalence and risk factors of disturbances in glucose metabolism. Between the years 1989 and 1992, a population-based survey of glucose tolerance was carried out in the Dutch city of Hoorn, which at that time was a medium-sized town of about 57 000 residents with a mixed rural and urban population in the West-Friesland region of The Netherlands. As the main goal of the study was to estimate the prevalence of pre-diabetes and diabetes in the general population, the only inclusion criteria consisted of being an inhabitant of Hoorn, aged 50–75 years and able to provide consent. Of the eligible ∼11 500 men and women, 3553 were randomly selected from the municipal registry. Of those 3553 men and women, 71.5% agreed to participate, with the nonparticipants being older (63.1 vs 61.7 years). The nonparticipants did not differ from our study population with respect to sex or self-reported diabetes. In addition to the nonparticipants, 56 non-Western descent participants were excluded, resulting in the Hoorn Study cohort of 2484 participants.2 The baseline characteristics of the Hoorn Study are shown in Table 1. The participants were aged 61.7 ± 7.4 years, 54.1% were male, their body mass index (BMI) was 26.6 ± 3.6 kg/m2, 22.2% had pre-diabetes and 11.7 % had diabetes, according to the World Health Organization (WHO) 2011 criteria.4 All participants provided informed consent and the study was approved by the Medical Ethical Committee of the VU University Medical Centre, Amsterdam, The Netherlands. Baseline characteristics of the participants in the Hoorn Study and the New Hoorn Study Comparison of both cohorts was done using linear and logistic regression, corrected for age and sex NA, not available; HOMA, HOmeostatic Model Assessment. Baseline characteristics of the participants in the Hoorn Study and the New Hoorn Study Comparison of both cohorts was done using linear and logistic regression, corrected for age and sex NA, not available; HOMA, HOmeostatic Model Assessment. Between the years 2006 and 2007, again a population-based survey was carried out in the city of Hoorn, which by then was a city of about 68 000 residents with a mixed rural and urban population. As the main goal of the study was to estimate the prevalence of pre-diabetes and diabetes in the general population, the only inclusion criteria consisted of being an inhabitant of Hoorn, aged 40-65 years and able to provide consent. Of the eligible ∼21 000 men and women, 6180 were randomly selected from the municipal registry. Of these 6180 men and women, 45.4% agreed to participate, with the nonparticipants being younger (51.5 vs 53.4 years). The nonparticipants did not differ from our study population with respect to sex or self-reported diabetes.3 The baseline characteristics of the 2807 participants of the New Hoorn Study population are shown in Table 1, with 125 participants being of non-Western descent, who in contrast to the Hoorn Study cohort were not excluded. In addition, the participants were aged 53.4 ± 6.7 years, 53.5% were male, their BMI was 26.3 ± 4.0 kg/m2, 16.6% had pre-diabetes and 7.1 % had diabetes according to the WHO 2011 criteria.4 All participants provided informed consent and the study was approved by the Medical Ethical Committee of the VU University Medical Centre, Amsterdam, The Netherlands. The set-ups of the Hoorn Study and the New Hoorn Study were nearly identical, except for the inclusion criteria of age (50–75 versus 40-65 years) and the time period in which we conducted the study (1989 versus 2006). In Table 1, we compared the baseline characteristics of the Hoorn Study participants with the New Hoorn Study participants, corrected for age and sex. Compared with the Hoorn Study participants, the participants for the New Hoorn Study were less often female, had a higher educational level, were less often smokers and had a similar BMI. In addition, compared with the Hoorn Study participants, the participants for the New Hoorn Study had less often type 2 diabetes, had less often hypertension and were less often diagnosed with cardiovascular disease (Table 1). Participants from the Hoorn Study have been followed up via several visits to our study centre and via examining their medical records.2,5 The flowchart for the visits is provided in Figure 1. In brief, a physical re-examination was conducted in 1990-91, which repeated the measurements from the baseline visit with additional extensive diabetes complications measurements.6,7 At that visit, only a subset of the cohort (n = 631), with an equal number of participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes, were recruited. During the follow-up in 1996-98, 2086 participants from the baseline visit (1989-90) were invited and the measurements of the baseline visit were repeated among 1513 participants.8 For follow-up in the year 2000-01, we invited all those who had diabetes at the 1996-98 visit and a random sample of individuals with NGT and IGT at the 1996-98 visit. An additional 188 new cases of people with type 2 diabetes from another screening study from the Hoorn region were invited,9 resulting in a total of 831 participants at the 2000-01 visit, at which the baseline measures and extensive diabetes complications measures were repeated.10 For the follow-up in the year 2005-07, three groups of participants were selected based on their profile at the examination in 2000-01. The first group had incident type 2 diabetes in 2000-01, and the other two groups did not have type 2 diabetes but either had the metabolic syndrome (≥ 3 criteria) or 0-1 metabolic syndrome factors in 2000-01. This resulted in a total of 280 participants who were included in the 2005-07 visit at which the baseline measures and extensive diabetes complications measures were repeated.11 For the follow-up in the year 2007-09, all surviving participants of the visit in 2000-01, including the new cases of type 2 diabetes from another screening study from the Hoorn region, were invited.9 This resulted in a total of 454 participants who were included in the 2007-09 visit, at which the baseline measures and extensive diabetes complications measures were repeated.12 Flowchart for the visits of the Hoorn study cohort. Finally, in addition to physical follow-up visits, all participants are still actively followed up for vital status by linkage with the municipality register and for occurrence of chronic diseases, with a special focus on cardiovascular disease and cancer as well as cause-specific mortality, by checking their medical records.5 The follow-up is complete until January 2009. At that date, 1362 participants of the first visit in 1989 were still alive, 879 had died and 243 were lost to follow-up. During follow-up, 27.6% of the participants were diagnosed with cardiovascular disease, including 6.7% with angina pectoris, 5.1% with myocardial infarction, 8.2% with congestive heart failure, 5.7% with stroke or transient ischaemic attack and/or 4.6% with peripheral disease. Participants from the New Hoorn Study have also been followed up by two visits to our study centre and by their medical records.3,5 Furthermore, in 2010-11, we conducted an additional measurement of the New Hoorn Study in a subsample of 206 participants, in which an equal number of participants with normal glucose metabolism (NGM) and impaired glucose metabolism (IGM) were included.13 In a follow-up visit of the total cohort, which was conducted in 2013-15, 1734 participants were included.14 For a detailed flow chart, see Figure 2. As in the Hoorn Study, all participants of the New Hoorn Study are still checked for their vital status through linkage with the municipality register and for occurrence for chronic diseases by checking their medical records.5 The follow-up is complete up tp 1 January 2011. To date, 2732 participants of the first visit in 200607 are still alive, 75 had died and none were lost to follow-up. During follow-up, 20.3% of the participants were diagnosed with cardiovascular disease, including 6.0% with angina pectoris, 4.2% with myocardial infarction, 4.6% with congestive heart failure, 2.9% with stroke or transient ischaemic attack and/or 2.6% with peripheral disease. Flowchart for the visits of the New Hoorn study cohort. For both the Hoorn Study and the New Hoorn Study, the following procedure was followed for all visits. Data were collected during a visit to our study centre in the city of Hoorn, located in The Netherlands. Participants came after an overnight fast and they were instructed to refrain from eating and drinking (except for drinking water) from 8:00pm the night before the visit, and from drinking alcohol and smoking from 5:00pm the day before the visit. Participants who had not been following these instructions were asked to reschedule their visit. Data were collected by research nurses according to standard operating procedures, and all visits were scheduled on weekdays. All visits have corresponding measurements, including: glucose metabolism determined by fasting plasma glucose, 75-g oral glucose tolerance test (OGTT) and HbA1c; anthropometrics; blood plasma lipid levels including triglycerides, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL); albumin/creatinine ratio; blood pressure; self-reported family history of diabetes, medication use, disease history, diabetes-related complaints, physical activity, smoking behaviour, alcohol intake and socioeconomic status; and a validated food frequency questionnaire.15,16 Moreover, the visits with additional diabetes complication measures included extensive physical diabetes complications measurements such as a retinopathy screening17 and electrocardiography.18 At all visits additional measurements have been conducted, which vary from visit to visit. For example, during the 2000–01 visit we collected DNA on which genome-wide single nucleotide polymorphism genotyping (GWAS) was performed,19 and cognition was measured in 2005–07.11Table 2 presents an overview of all the measurements conducted and at what time points they were collected. Overview of the measurements taken at which time points in the Hoorn Study cohort S, collected in subgroup, including percentage collected; –, not collected; X, collected in whole group. Overview of the measurements taken at which time points in the Hoorn Study cohort S, collected in subgroup, including percentage collected; –, not collected; X, collected in whole group. Almost all measures taken in the Hoorn Study visits have been also taken in the New Hoorn Study visits. Similarly, additional measures vary from visit to visit. For example, during the first follow-up in a subgroup, detailed measurements of microvascular function by capillary video microscopy were taken,13 and at the 7-year follow-up, data on sleep characteristics were collected. Table 3 represents an overview of all the measurements conducted. Overview of the measurements taken at which time points in the New Hoorn Study cohort S, collected in subgroup, including percentage collected; –, not collected. Overview of the measurements taken at which time points in the New Hoorn Study cohort S, collected in subgroup, including percentage collected; –, not collected. Finally, in both cohorts and at almost all visits, we collected DNA, urine, plasma, serum and citrate plasma samples and stored these at −80°C for future use. Table 4 provides an overview of the stored materials and time points of collection. The following analyses have been performed in (part of) these biobank samples: isolation of DNA; genotyping of several single nucleotide polymorphisms; and additional biomarker analysis, such as vitamin D. The possibility of additional assays and/or in silico analyses exists and requests for collaborations can be addressed to the steering committee of the Hoorn studies. Please visit our website www.hoornstudies.com for an up to date version of Tables 2, 3 and 4, including new visits and new variables. Overview of the type of materials and time points of stored biobank materials of all Hoorn Study cohort and New Hoorn Study cohort visits –: not collected; S, collected in subgroup; X, collected in whole group. Overview of the type of materials and time points of stored biobank materials of all Hoorn Study cohort and New Hoorn Study cohort visits –: not collected; S, collected in subgroup; X, collected in whole group. The Hoorn Study has resulted thus far in over 175 publications. Key findings from this cohort include the following. Both fasting glucose and impaired glucose metabolism, and particularly presence of both, are associated with cumulative incidence of type 2 diabetes.8 Mild to moderate loss of renal function is strongly associated with an increased risk of cardiovascular mortality.20 Carotid and femoral stiffness are more prevalent in people with type 2 diabetes21 and are independently associated with incident cardiovascular events and all-cause mortality.22 Endothelial dysfunction is associated with a range of diabetes complications, such as depression,23 cognitive dysfunction,24 retinopathy and cardiovascular disease.25 Higher B-type natriuretic peptide (BNP) levels in a non-heart failure range are associated with an increased left ventricular (LV) mass and deteriorated LV diastolic function, particularly in individuals with type 2 diabetes.26 Additionally, as results from the Hoorn Study showed that diabetes care in The Netherlands was subpar, we started with centrally organized diabetes care in the region of West Friesland in 1996, resulting in the Hoorn Diabetes Care System cohort.27 Finally, data of the Hoorn Study contribute to many consortia, including the Emerging Risk Factors Collaboration,28 the USE-IMT initiative,29 the PROG-IMT project,30 the DETECT-2 collaboration,31 the InterConnect collaboration32 and the ABI collaboration.33 The New Hoorn Study resulted in five publications thus far. Key findings from this cohort include: In patients with known diabetes, correlations between glucose and A1c are strong, but are moderate in the general population; and the advantage of A1c compared with OGTT for the diagnosis of diabetes was limited.3 Depressive symptoms, but not anxiety, are associated with glucose metabolism.34 A combined risk allele score for single nucleotide polymorphisms in four known fasting plasma glucose loci are associated with fasting plasma glucose and HbA1c in non-diabetic participants.19 The New Hoorn Study also contributes data to several consortia, such as the DIRECT consortium,35 the ODIN consortium36 and the InterConnect collaboration.32 The main strengths of the Hoorn Study are its prospective design with long follow-up of over 25 years. Another strength is the use of OGTT and HbA1c for detection of (pre-)diabetes and the availability of many vascular risk factors, such as intima-media thickness, ankle-brachial index, vascular stiffness and cardiac function. Another strength is the availability of a comprehensive set of confounders, a biobank and five follow-up measurements allowing us to track risk factors of cardiometabolic diseases over time. The main limitation of the study is its relatively small sample size (< 3000 participants), resulting in low power to study infrequently occurring chronic diseases, such as certain types of cancer, or to study certain subgroups. The main strengths of the New Hoorn Study are, again, its prospective design with a repeat follow-up examination, the use of OGTT and HbA1c for detection of (pre-)diabetes and availability of a broad set of cardiometabolic risk factors as well as a biobank. In addition, we collected extensive information on psychosocial risk factors of chronic diseases. The main limitation of the New Hoorn Study is, again, its relatively small sample size and, thus far, short follow-up time. Data from the Hoorn Study and the New Hoorn Study are available for researchers. After approval of a data request by the steering committee of the Hoorn Studies, a collaboration agreement will be signed and the data can be obtained. For more information, please contact [hoornstudy@vumc.nl]. In past years, funding for the Hoorn Study was provided by several different sponsors at certain points in time, including: the VU University Medical Center of Amsterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMW), the Dutch Diabetes Research Foundation and the Netherlands Heart Foundation. Funding for the New Hoorn Study was provided by: the VU University Medical Center of Amsterdam, Novartis Pharma B.V, the European Union and the Innovative Medicine Initiative. Profile in a nutshell The Hoorn Study and New Hoorn Study were established to investigate the prevalence and risk factors of impaired glucose metabolism, diabetes and diabetes-related complications in a predominately Western European population, and whether increasing rates of longevity, physical inactivity and obesity affect the prevalence and risk factors of disturbances in glucose metabolism. Participants were recruited in two time periods, 1989-91 and 2006-07, from the Dutch city of Hoorn, which is a medium-sized town in the West Friesland region of The Netherlands. In total, 5291 participants joined the baseline visit, in which we determined glucose metabolism, anthropometrics, blood plasma lipid levels, renal function, blood pressure, family history of diabetes and several self-reported socioeconomic status and behavioural measures. Moreover, in subgroups follow-up included assessment of diabetes complications retinopathy, nephropathy, autonomic or peripheral nervous system dysfunction and cardiac and vascular structure and function. At all visits, additional measurements have been conducted, which vary from visit to visit. From each participant, several samples of DNA, plasma, serum, citrate and urine were stored in our biobank for future use. Over the past 25 years, the Hoorn Study cohort has been followed up twice and subgroups of the Hoorn Study five times. In the past 10 years, the New Hoorn Study has been followed up once and subgroups of the New Hoorn Study also once. In addition to physical follow-up, all participants are followed up for vital status by linkage with the municipality register, and for occurrence of chronic diseases and causes of death by checking their medical records. Hoorn Study and New Hoorn Study data are accessible via a collaboration agreement with the steering committee, contact [hoornstudy@vumc.nl]. We appreciate the corporation of the participants and research assistants who have been involved in the Hoorn Study and New Hoorn Study. We would like to thank Tootje Hoovers and Jolanda Bosman as well as all the researchers previously involved for the organization of both studies. F.R. and J.W.B. researched data and wrote the manuscript. A.A.vd.H., L.M.’t.H. and P.J.E. reviewed and edited the manuscript. G.N, J.M.D. and C.D.S. conceived of and designed the study and reviewed and edited the manuscript. Conflict of interest: The authors have no involvements that might raise the question of bias in the work reported or in the conclusions, implications or opinions stated.
No takes yet. Share an insight, caveat, or question.
Rutters et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: